Study suggests experimental drug dismantles 2 key proteins that help tumors survive, adapt and resist treatment
Scientists from Roswell Park Comprehensive Cancer Center report that the investigational anticancer agent FL118 functions as a dual molecular glue degrader that directly targets and degrades the proteins DDX5 and UbE2T, two emerging therapeutic targets linked to cancer survival mechanisms.
<p>Scientists from Roswell Park Comprehensive Cancer Center report that the investigational anticancer agent FL118 functions as a dual molecular glue degrader that directly targets and degrades the proteins DDX5 and UbE2T, two emerging therapeutic targets linked to cancer survival mechanisms.</p>